OVID News and Press, Ovid Therapeutics Inc. From 09/04/19

OpGen (NASDAQ: OPGN ) +77%  to merge with Curetis N.V. More news on: OpGen, Inc., Top Ships Inc., The Michaels Companies, Inc., Stocks on the move, Read more ...

Atreca (NASDAQ: BCEL ) initiated with Buy rating and $30 (61% upside) price target at Roth Capital. More news on: Atreca, Inc., Constellation Pharmaceuticals, Inc., Ovid Therapeutics Inc., Healthcare stocks news, Stocks on the move, , Read more ...

NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced its participation in two upcoming investor conferences in Sep...

Ovid Therapeutics (NASDAQ: OVID ): Q2 GAAP EPS of -$0.34 beats by $0.11 . More news on: Ovid Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Phase 3 NEPTUNE Trial of OV101 in Angelman Syndrome on Track to Enroll the First Patients in the Third Quarter of 2019 Regulatory Authorities in the U.S. and Germany agree that NEPTUNE, if positive, could support the filings of an NDA and MAA for OV101 Interim Data from Open-Label ENDY...

Ovid Therapeutics Inc. ( OVID ) is a recently IPO-ed pharmaceutical company, established in 2014, IPO-ed in 2017. It targets unmet need in neurological diseases. Currently, they have 4 drugs in their pipeline, with one drug reaching its pivotal trial. OV101 or Gaboxadol, the lead drug, targe...

OVID stock continues to move higher for the fourth straight session and jumps another 10% this morning after Ovid Therapeutics’ (NASDAQ:OVID) product “OV101” won orphan drug designation by the European Commission. Another Key Announcement Ovid Therapeutics, which is...

Investors appear to be waking up to Ovid Therapeutics ( OVID +10% ). Shares have rallied almost  40%  this week. More news on: Ovid Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more ...

NEW YORK, July 02, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the European Commission (EC) has granted orphan drug desi...

NEW YORK, July 02, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the European Commission (EC) has granted orphan drug desi...